Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology

Masitinib, a highly selective protein kinase inhibitor, can sensitise gemcitabine-refractory cancer cell lines when used in combination with gemcitabine. Here we report a reverse proteomic approach that identifies the target responsible for this sensitisation: the deoxycytidine kinase (dCK). Masitin...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammam, Kahina, Saez-Ayala, Magali, Rebuffet, Etienne, Gros, Laurent, Lopez, Sophie, Hajem, Berengere, Humbert, Martine, Baudelet, Emilie, Audebert, Stephane, Betzi, Stephane, Lugari, Adrien, Combes, Sebastien, Letard, Sebastien, Casteran, Nathalie, Mansfield, Colin, Moussy, Alain, De Sepulveda, Paulo, Morelli, Xavier, Dubreuil, Patrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5681654/
https://www.ncbi.nlm.nih.gov/pubmed/29127277
http://dx.doi.org/10.1038/s41467-017-01582-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5681654/
https://www.ncbi.nlm.nih.gov/pubmed/29127277
http://dx.doi.org/10.1038/s41467-017-01582-5

Ejemplares similares